Lifeboat Foundation

Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up. This could decrease the mortality of patients affected by COVID-19, according to the peer-reviewed journal PHAGE: Therapy, Applications, and Research.

“The bacterial growth rate could potentially be reduced by the aerosol application of natural bacteriophages. These prey on the main species of bacteria known to cause respiratory failure,” says Marcin Wojewodzic, PhD, University of Birmingham (U.K.). Decreasing bacterial growth would also give the body more time to produce protective antibodies against the disease-causing coronavirus.

Used correctly, phages have an advantage here of being able to very specifically target the bacteria that cause secondary infections. They would remove the problematic bacterium but leave an otherwise fragile microbiome intact.” Martha Clokie, PhD, Editor-in-Chief of PHAGE and Professor of Microbiology, University of Leicester (U.K.)

Continue reading “Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19)” »

A supersensitive dopamine detector can help in the early diagnosis of several disorders that result in too much or too little dopamine, according to a group led by Penn State and including Rensselaer Polytechnic Institute and universities in China and Japan.

Dopamine is an important neurotransmitter that can be used to diagnose disorders such as Parkinson’s disease, Alzheimer’s disease and schizophrenia.

“If you can develop a very sensitive, yet simple-to-use and portable, detector that can identify a wide range of dopamine concentration, for instance in sweat, that could help in non-invasive monitoring of an individual’s health,” said Aida Ebrahimi, assistant professor of electrical engineering, Penn State, and a corresponding author on a paper published Aug. 7 in Science Advances.

Four Canadians battling incurable cancer have been approved by the Minister of Health, Patty Hajdu, to use psilocybin therapy in the treatment of their end-of-life distress. These 4 patients mark the first publicly-known individuals to receive a legal exemption from the Canadian Drugs and Substances Act to access psychedelic therapy, and the first known patients to legally use psilocybin since the compound became illegal in Canada in 1974. The decision comes after over 100 days of waiting for a response.

“ I would like to personally thank the Hon. Minister Hajdu and the team at the Office of Controlled Substances for the approval of my section 56 exemption. This is the positive result that is possible when good people show genuine compassion. I’m so grateful that I can move forward with the next step of healing” says Thomas Hartle, one the section 56 applicants battling cancer, from Saskatoon Saskatchewan.

Laurie Brooks, another applicant from British Columbia facing end-of-life distress states: “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgement of the pain and anxiety that I have been suffering with means a lot to me, and I am feeling quite emotional today as a result. I hope this is just the beginning and that soon all Canadians will be able to access psilocybin, for therapeutic use, to help with the pain they are experiencing, without having to petition the government for months to gain permission. Thanks also to TheraPsil for helping the four of us in this fight. To Thomas Hartel and the other two patients – I think of you often and wish you only good things, especially good health!”

Many organizations will likely look to technology as they face budget cuts and need to reduce staff. “I don’t see us going back to the staffing levels we were at prior to COVID,” says Brian Pokorny, the director of information technologies for Otsego County in New York State, who has cut 10% of his staff because of pandemic-related budget issues. “So we need to look at things like AI to streamline government services and make us more efficient.”

For 23 years, Larry Collins worked in a booth on the Carquinez Bridge in the San Francisco Bay Area, collecting tolls. The fare changed over time, from a few bucks to $6, but the basics of the job stayed the same: Collins would make change, answer questions, give directions and greet commuters. “Sometimes, you’re the first person that people see in the morning,” says Collins, “and that human interaction can spark a lot of conversation.”

But one day in mid-March, as confirmed cases of the coronavirus were skyrocketing, Collins’ supervisor called and told him not to come into work the next day. The tollbooths were closing to protect the health of drivers and of toll collectors. Going forward, drivers would pay bridge tolls automatically via FasTrak tags mounted on their windshields or would receive bills sent to the address linked to their license plate. Collins’ job was disappearing, as were the jobs of around 185 other toll collectors at bridges in Northern California, all to be replaced by technology.

Continue reading “Millions of Americans Have Lost Jobs in the Pandemic — And Robots and AI Are Replacing Them Faster Than Ever” »

A small DNA-testing company that just months ago was trying to get its footing in consumer genetics is now part of an effort to make U.K. hospitals safer during the pandemic.

The company, DnaNudge, won a 161-million pound ($211 million) order for 5,000 machines and a supply of cartridges to test patients for the new coronavirus in hundreds of the National Health Service hospitals.

Sanofi and GlaxoSmithKline (GSK) will be awarded up to $2.1 billion by the U.S. Departments of Health and Human Services (HHS) and Defense (DoD) toward development and manufacturing of the recombinant protein-based COVID-19 vaccine being produced by the companies, they and the U.S. government said.

HHS and DoD are providing the funding as part of Operation Warp Speed—the program through which President Donald Trump’s administration has committed the nation to delivering 300 million vaccine doses protecting against SARS-CoV-2 by January 2021.

“The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” HHS Secretary Alex Azar II stated.

When baboons experience trauma in early life, they have higher levels of stress hormones in adulthood—a potential marker of poor health—than their peers who don’t experience trauma, even if they have strong social relationships as adults, according to a study led by a University of Michigan researcher.

The study examined the links between childhood adversity, adult social relationships and glucocorticoid concentrations. The goal was to determine whether one of the reasons that baboons who experience early trauma live shorter, less healthy lives was because they fail to develop strong social relationships in adulthood, which could be beneficial to health.

U-M biological anthropologist Stacy Rosenbaum and her co-authors found that while early life adversity didn’t strongly affect baboons’ ability to have social relationships, any positive effect of those relationships was much smaller than the large negative effects of early life trauma.

#COVID19: There is overwhelming scientific evidence that a mid-range air humidity has significant benefits for human health. It is very possible for us to be managing the indoor air quality of our public buildings in line with this evidence. The time has come for regulations on indoor air quality to include a humidity level of 40-60u0025RH. This is the optimal level for our respiratory immune system, and will reduce the spread of seasonal respiratory illnesses and their burden on society.nn

There is now overwhelming scientific evidence that a mid-range air humidity has significant benefits for human health. It is very possible for us to be managing the indoor air quality of our public buildings in line with this evidence. The time has come for regulations on indoor air quality to include a humidity level of 40–60%RH. This is the optimal level for our respiratory immune system, and will reduce the spread of seasonal respiratory illnesses and their burden on society.

Continue reading “Take action and join me in the fight against respiratory infections! Relative humidity of 40-60% in buildings will reduce respiratory infections and save lives” »

Researchers from the Icahn School of Medicine used a novel genetic sequencing technology to identify the genetic cause of—and a treatment for—a previously unknown severe auto inflammatory syndrome affecting an 18-year-old girl since infancy.

The technology, tailored to the patient’s own genetic code at a single cell level, helped the researchers characterize an unknown mutation in a gene called JAK1 that caused the patient’s immune system to be permanently turned on, resulting in rashes over much of her skin, growth abnormalities, kidney failure, allergic hypersensitivities, and an unusual inflammatory condition throughout the digestive tract.

The study, led by Dusan Bogunovic, Ph.D., Associate Professor of Microbiology, and Pediatrics, at the Icahn School of Medicine at Mount Sinai, faculty member of The Mindich Child Health and Development Institute and the Precision Immunology Institute at Mount Sinai, and Director of the Center for Inborn Errors of Immunity, was published in the August 3 issue of the journal Immunity. The discovery points toward new ways to study how genetic diseases manifest and presents a model of personalized diagnosis and treatment for patients with genetic diseases.